arrow
L

Lisa Salvatore

catholic university of the sacred heart
H指数:41
被引数:7,832

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Germline pathogenic variants identification through comprehensive cancer genome profiling

通过全面癌症基因组分析鉴定生殖系致病性变异

2026-10-270
OAAI
Switch from cetuximab to panitumumab during encorafenib-based therapy in BRAF V600E mutated metastatic colorectal cancer: An international multicenter analysis from the AGEO group
2026-01-010
OAAI
Clinicomics for Predicting HER2 Expression in Metastatic Colorectal Cancer: A Multicenter Machine Learning Analysis on Real-World Data

Clinicomics在预测转移性结直肠癌HER2表达中的应用:一项基于真实世界数据的 multicenter 机器学习分析

2025-12-010
PRE
Long-term survival and prognostic factors after repeated metastasectomies in metastatic colorectal cancer: a 15-years retrospective study

结直肠癌转移患者重复转移灶切除术后的长期生存及预后因素:一项15年回顾性研究

2025-12-010
PRE
Prognostic impact of Geriatric 8 and comprehensive geriatric assessment in older patients with advanced pancreatic ductal adenocarcinoma

老年评估量表(Geriatric 8)和综合老年评估在晚期胰腺导管腺癌老年患者中的预后影响

2025-10-180
OAAI
Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial

KRASG12C突变化疗难治性转移性结直肠癌患者接受Sotorasib联合帕尼单抗或标准治疗(CodeBreaK 300):一项III期随机临床试验的结果

2025-08-110
OAAI
MRI-based radiomics predicts the pathologic response of colorectal liver metastases to systemic therapy: A multicenter study

基于MRI的放射组学预测结直肠癌肝转移对全身治疗的病理反应:一项多中心研究

2025-07-170
OA
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset

pT4N0结肠癌的预后影响与临床管理:来自大型、多中心、国际、真实世界数据集的数据

2025-07-150
OAAI
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies

FOLFOXIRI和FOLFOX/FOLFIRI两种一线方案,无论是否联合贝伐珠单抗,其相对剂量强度均会影响转移性结直肠癌患者的预后:TRIBE和TRIBE2研究的合并分析

2025-06-010
PRE
A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)

一项针对未治疗的II期/III期dMMR/MSI-H局部晚期直肠癌患者的多塔利单抗单药治疗的二期、单臂、开放标签研究(AZUR-1)

2025-02-210
OAAI
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
2025-02-010
OAAI
Detecting BRAF mutations in colorectal cancer in clinical practice: An Italian experts' position paper

在临床实践中检测结直肠癌的BRAF突变: 意大利专家的立场文件

2025-02-011
OAAI
The Impact of a Multidisciplinary Tumor Board (MDTB) in the Management of Colorectal Cancer (CRC)

多学科肿瘤委员会(MDTB)在结直肠癌(CRC)管理中的影响

2025-01-100
OA
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAFV600E-mutated metastatic colorectal cancer treated with targeted therapy
2025-01-070
OAAI
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort

阿柏西普为基础和贝伐珠单抗为基础的二线方案在转移性结直肠癌患者中的应用:一项多中心队列研究的倾向性评分加权分析

2025-01-020
OAAI
Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance
2024-12-041
OAAI